Kigtropin 200 IU 20iu/vial 10 Vials by Biotechnology

Usage

1. Reconstitute carefully: Add 2 mL of bacteriostatic water per 20 IU vial by directing the stream slowly down the inside wall — never inject directly onto the powder cake or shake the vial.
2. Allow to dissolve: Gently swirl (do not shake) until the lyophilised powder is fully dissolved and the solution is clear and colourless.
3. Draw your dose: Using a U-100 insulin syringe, draw the volume corresponding to your planned dose (e.g., 0.2 mL = 2 IU from a 2 mL reconstituted vial).
4. Select and clean the injection site: Choose a subcutaneous site — lower abdomen, outer thigh, or deltoid. Wipe with an alcohol swab and allow to dry fully before injecting.
5. Inject subcutaneously: Pinch a small fold of skin, insert the needle at 45–90°, inject slowly, then withdraw and apply light pressure. Rotate sites with every injection.
6. Time your injection for anti-aging benefit: For sleep and recovery-focused goals, administer 30–60 minutes before sleep to coincide with the body's natural nocturnal growth hormone release window; refrigerate the remaining reconstituted vial immediately at 2–8 °C.

Warnings

Frequently asked questions

What HGH dosage is considered the anti-aging range for adults?

The anti-aging dosage range for recombinant HGH is generally 1–3 IU per day, administered subcutaneously. This is substantially lower than athletic or body-recomposition protocols. At this range, the primary effects are improvements in skin collagen density, sleep quality, and energy — with a significantly lower incidence of joint fluid retention or glucose dysregulation compared to doses above 4 IU/day.

What documented effects does low-dose HGH have on skin elasticity and sleep?

Peer-reviewed studies have documented 7–15% increases in dermal skin thickness after 6 months of HGH administration at anti-aging doses. For sleep, growth hormone amplifies slow-wave and REM sleep stages, since the body's natural endogenous GH pulse coincides with these phases. Evening injection timing with Kigtropin maximises overlap with this nocturnal release window, supporting deeper, more restorative sleep cycles.

At what age does natural HGH production begin to decline noticeably?

Endogenous growth hormone output begins declining from the mid-twenties, falling at roughly 14–15% per decade — a progression termed somatopause in longevity medicine. By age 40, most adults have GH secretion at approximately 50% of their adolescent peak. This physiological decline correlates with reduced collagen production, disrupted sleep architecture, and lower baseline energy levels, which anti-aging HGH protocols are designed to partially address.

How do you reconstitute and store Kigtropin 20 IU vials after opening?

Reconstitute each 20 IU lyophilised vial with 2 mL of bacteriostatic water, injecting the water slowly down the vial wall — never shake. Once reconstituted, store the vial refrigerated at 2–8 °C and use within 20–25 days. Unopened lyophilised vials should be kept refrigerated; avoid freeze-thaw cycles, which degrade peptide integrity. Discard any vial showing particulate matter or cloudiness.

Can Kigtropin 20 IU vials be drawn with an insulin syringe, and what needle gauge is recommended?

Yes — insulin syringes (U-100, 1 mL) are the standard tool for subcutaneous HGH administration. For a 2 IU dose from a 2 mL reconstituted vial, draw 0.2 mL. A 29–31 gauge, 4–8 mm needle minimises injection discomfort. Common subcutaneous injection sites include the abdomen, outer thigh, and deltoid area; rotate sites with each injection to prevent lipohypertrophy. (2) angle_used

Manufacturer

Biotechnology applies a dual-stage analytical quality control process to its recombinant somatotropin range: High-Performance Liquid Chromatography (HPLC) is used to confirm full 191-amino-acid peptide chain integrity and batch purity, while LAL (Limulus Amebocyte Lysate) endotoxin assays validate injection safety at the lot level. Manufacturing takes place in a GMP-certified facility operating under current Good Manufacturing Practice guidelines, with documented in-process and release testing at each production stage. This framework is designed to ensure that every Kigtropin vial reaching the end user carries verified biological potency — not just labelled potency.